CYMER INC
10-Q, 2000-08-11
PHOTOGRAPHIC EQUIPMENT & SUPPLIES
Previous: AMERICAN BIO MEDICA CORP, 10KSB40, EX-27.1, 2000-08-11
Next: CYMER INC, 10-Q, EX-10.1, 2000-08-11



<PAGE>

                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                    FORM 10-Q

/X/      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934
         For the quarterly period ended June 30, 2000

                                                        OR

/ /      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT
         OF 1934
         For the transition period from __________ to ____________

                         Commission file number 0-21321

                                   CYMER, INC.
             (Exact name of registrant as specified in its charter)

                  Nevada                                  33-0175463
    (State or other jurisdiction of         (I.R.S. Employer Identification No.)
    incorporation or organization)

16750 Via Del Campo Court, San Diego, CA                    92127
(Address of principal executive offices)                 (Zip Code)

Registrant's telephone number, including area code   (858) 385-7300

Former name, former address and former fiscal year, if changed since last
report.
 N/A


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

Yes   X           No
    -----            ----

The number of shares of Common Stock, with $0.001 par value, outstanding on
August 7, 2000 was 29,186,042.


<PAGE>

                                   CYMER, INC.

                                    FORM 10-Q

                       FOR THE QUARTER ENDED JUNE 30, 2000

                                      INDEX

<TABLE>
<CAPTION>
                                                                                                PAGE
<S>                                                                                            <C>
PART I.        FINANCIAL INFORMATION

ITEM 1.        Consolidated Financial Statements (unaudited)

               Consolidated Balance Sheets as of December 31,
                  1999 and June 30, 2000                                                          3

               Consolidated Statements of Operations for the
                  three and six months ended June 30, 1999 and 2000                               4

               Consolidated Statements of Cash Flows for the
                  six months ended June 30, 1999 and 2000                                         5

               Notes to Consolidated Financial Statements                                         7

ITEM 2.        Management's Discussion and Analysis of Financial
                  Condition and Results of Operations                                            10

ITEM 3.        Quantitative and Qualitative Disclosures About
                   Market Risk                                                                   26

PART II.       OTHER INFORMATION

ITEM 1.        Legal Proceedings                                                                 27

ITEM 2.        Changes in Securities and Use of Proceeds                                         27

ITEM 3.        Defaults upon Senior Securities                                                   27

ITEM 4.        Submission of Matters to a Vote of Security Holders                               27

ITEM 5.        Other Information                                                                 28

ITEM 6.        Exhibits and Reports on Form 8-K                                                  28

SIGNATURE PAGE                                                                                   29
</TABLE>


                                       2
<PAGE>

                          PART I. FINANCIAL INFORMATION

CYMER, INC.
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(IN THOUSANDS, EXCEPT SHARE DATA)
-------------------------------------------------------------------------------
<TABLE>
<CAPTION>
                                                                                          ------------  ------------
                                                                                          DECEMBER 31,    JUNE 30,
                                                                                          ------------  ------------
ASSETS                                                                                        1999         2000
<S>                                                                                        <C>          <C>
CURRENT ASSETS:
   Cash and cash equivalents                                                               $  75,765    $  92,887
   Short-term investments                                                                     97,564      105,430
   Accounts receivable - net                                                                  69,251       77,660
   Foreign exchange contracts receivable                                                      21,706       28,644
   Inventories                                                                                51,409       65,978
   Deferred income taxes                                                                      16,360       16,353
   Prepaid expenses and other                                                                  3,110        3,514
                                                                                          ------------  ------------
          Total current assets                                                               335,165      390,466

PROPERTY - net                                                                                56,921       72,234
LONG-TERM INVESTMENTS                                                                         19,760        3,508
DEFERRED TAXES - NON-CURRENT                                                                   8,562        7,508
OTHER ASSETS                                                                                   6,413        6,344
                                                                                          ------------  ------------

TOTAL ASSETS                                                                               $ 426,821    $ 480,060
                                                                                          ============  ============

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
   Accounts payable                                                                        $  20,599    $  22,365
   Accrued and other liabilities                                                              52,292       61,281
   Foreign exchange contracts payable                                                         24,276       28,285
   Income taxes payable                                                                        6,482       11,756
   Revolving loan                                                                             18,395       17,718
                                                                                          ------------  ------------
          Total current liabilities                                                          122,044      141,405
                                                                                          ------------  ------------

LONG-TERM LIABILITIES:
  Convertible subordinated notes                                                             172,500      172,335
  Other liabilities                                                                            3,271        3,191
MINORITY INTEREST                                                                              2,113        1,769
COMMITMENTS AND CONTINGENCIES (Note 7)

STOCKHOLDERS' EQUITY:
   Preferred Stock - authorized 5,000,000 shares; $.001 par value,
     no shares issued or outstanding
   Common stock - authorized 50,000,000 shares; $.001 par value,
     issued and outstanding 28,435,000 and 29,141,000 shares                                      28           29
   Paid-in capital                                                                           125,623      133,313
   Treasury stock at cost (2,000,000 common shares)                                          (24,871)     (24,871)
   Accumulated other comprehensive loss                                                       (3,620)      (2,110)
   Retained earnings                                                                          29,733       54,999
                                                                                          ------------  ------------
          Total stockholders' equity                                                         126,893      161,360
                                                                                          ------------  ------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                                 $ 426,821    $ 480,060
                                                                                          ============  ============
</TABLE>

See notes to unaudited consolidated financial statements.


                                       3
<PAGE>

CYMER, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(IN THOUSANDS, EXCEPT PER SHARE DATA)
-------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                   FOR THE THREE MONTHS         FOR THE SIX MONTHS
                                                      ENDED JUNE 30,              ENDED JUNE 30,
                                                ------------------------     -----------------------
                                                    1999           2000          1999        2000
<S>                                               <C>          <C>          <C>          <C>
REVENUES:
   Product sales ..............................   $  43,378    $  85,802    $  83,202    $ 166,333
   Other ......................................          31          449          299          534
                                                  ---------    ---------    ---------    ---------
          Total revenues ......................      43,409       86,251       83,501      166,867
                                                  ---------    ---------    ---------    ---------

COSTS AND EXPENSES:
   Cost of product sales ......................      28,395       43,645       56,511       89,796
   Research and development ...................       7,863       10,639       15,315       21,402
   Sales and marketing ........................       3,465        4,738        6,996        8,536
   General and administrative .................       3,172        4,723        5,966        9,297
                                                  ---------    ---------    ---------    ---------
          Total costs and expenses ............      42,895       63,745       84,788      129,031
                                                  ---------    ---------    ---------    ---------

OPERATING INCOME (LOSS) .......................         514       22,506       (1,287)      37,836
                                                  ---------    ---------    ---------    ---------

OTHER INCOME (EXPENSE):
   Foreign currency exchange gain (loss) - net          161          (37)         (74)         (20)
   Interest and other income ..................       1,653        2,786        3,417        5,174
   Interest and other expense .................      (2,807)      (3,255)      (5,570)      (6,163)
                                                  ---------    ---------    ---------    ---------

          Total other expense - net ...........        (993)        (506)      (2,227)      (1,009)
                                                  ---------    ---------    ---------    ---------

INCOME (LOSS) BEFORE INCOME TAX
   PROVISION AND MINORITY INTEREST ............        (479)      22,000       (3,514)      36,827
                                                  ---------    ---------    ---------    ---------

INCOME TAX PROVISION ..........................         758        6,600         --         11,048
MINORITY INTEREST .............................        (252)        (125)        (273)        (329)
                                                  ---------    ---------    ---------    ---------

NET INCOME (LOSS) .............................   $  (1,489)   $  15,275    $  (3,787)   $  25,450
                                                  =========    =========    =========    =========

EARNINGS (LOSS) PER SHARE:
Basic:
     Earnings (loss) per share ................   $   (0.05)   $    0.53    $   (0.14)   $    0.88
                                                  =========    =========    =========    =========
     Weighted average common shares outstanding      27,795       29,065       27,592       28,888
                                                  =========    =========    =========    =========
Diluted:
     Earnings (loss) per share ................   $   (0.05)   $    0.50    $   (0.14)   $    0.82
                                                  =========    =========    =========    =========
     Weighted average common and potential
          common shares outstanding ...........      27,795       30,745       27,592       31,001
                                                  =========    =========    =========    =========
</TABLE>

See notes to unaudited consolidated financial statements.


                                       4
<PAGE>

CYMER, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(IN THOUSANDS)
-------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                             FOR THE SIX MONTHS ENDED
                                                                                     JUNE 30,
                                                                           -----------------------------
                                                                                1999        2000
<S>                                                                         <C>           <C>
OPERATING ACTIVITIES:
   Net income (loss) ....................................................   $  (3,787)   $  25,450
   Adjustments to reconcile net income (loss) to net cash
     provided by operating activities:
     Depreciation and amortization                                              8,515        9,289
     Minority interest                                                            273          329
     Deferred income taxes ..............................................        (514)          --
     (Gain) loss on disposal of property ................................         (45)         494
     Change in assets and liabilities:
       Accounts receivable - net ........................................      (5,813)      (9,880)
       Foreign exchange contracts receivable ............................       4,536       (7,669)
       Inventories ......................................................      (2,491)     (15,004)
       Prepaid expenses and other assets ................................        (990)      (3,550)
       Accounts payable                                                         4,765        1,790
       Accrued and other liabilities                                            6,692       12,915
       Foreign exchange contracts payable ...............................      (7,124)       4,860
       Income taxes payable                                                       275        5,286
                                                                            ---------    ---------
          Net cash provided by operating activities                             4,292       24,310
                                                                            ---------    ---------


INVESTING ACTIVITIES:
   Acquisition of property ..............................................      (9,888)     (25,045)
   Purchases of investments .............................................     (62,354)     (95,182)
   Proceeds from sold or matured investments ............................      81,785      103,630
   Acquisition of minority interest .....................................          --       (1,104)
                                                                            ---------    ---------
          Net cash provided by (used in) investing activities ...........       9,543      (17,701)
                                                                            ---------    ---------
FINANCING ACTIVITIES:
   Net borrowings (payments) under revolving loan and security agreements       4,726           --
   Proceeds from issuance of common stock ...............................       3,018        7,526
   Dividends paid to minority shareholder of foreign subsidiary .........          --         (183)
   Payments on capital lease obligations ................................        (284)        (316)
                                                                            ---------    ---------
          Net cash provided by financing activities                             7,460        7,027
                                                                            ---------    ---------
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND
  CASH EQUIVALENTS                                                              1,137        3,486
                                                                            ---------    ---------

NET INCREASE IN CASH AND CASH EQUIVALENTS ...............................      22,432       17,122
CASH AND CASH EQUIVALENTS AT BEGINNING  OF PERIOD .......................      53,130       75,765
                                                                            ---------    ---------

CASH AND CASH EQUIVALENTS AT END OF PERIOD ..............................   $  75,562    $  92,887
                                                                            =========    =========


                                       5
<PAGE>


SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
   Interest paid ...................................                          $3,337   $3,483
   Income taxes paid ...............................                          $1,101   $4,589
                                                                              ======   ======

SUPPLEMENTAL DISCLOSURE OF NON CASH FLOW ACTIVITIES:
   Conversion of debt to equity ....................                            --     $  165
                                                                              ======   ======
</TABLE>

See notes to unaudited consolidated financial statements.


                                       6
<PAGE>

                                   CYMER, INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                    THREE AND SIX MONTHS ENDED JUNE 30, 2000
                                   (UNAUDITED)

1.   BASIS OF PRESENTATION

          The accompanying consolidated financial information has been prepared
by Cymer, Inc., and its wholly-owned and majority-owned subsidiaries
(collectively "Cymer"), without audit, in accordance with the instructions to
Form 10-Q and therefore does not include all information and footnotes necessary
for a fair presentation of financial position, results of operations and cash
flows in accordance with generally accepted accounting principles.

         PRINCIPLES OF CONSOLIDATION - The consolidated financial statements
include the accounts of Cymer, Inc., its wholly-owned subsidiaries, Cymer Japan,
Inc. (Cymer Japan), Cymer Singapore Pte Ltd. (Cymer Singapore), Cymer B.V. in
the Netherlands (Cymer B.V.), and Cymer Southeast Asia, Inc., in Taiwan (Cymer
SEA) and its majority-owned subsidiary, Cymer Korea, Inc. (Cymer Korea). Cymer,
Inc. owns 70% of Cymer Korea. During the first quarter of 2000, Cymer, Inc.
acquired the 25% minority interest in Cymer SEA for $1,104,000. Cymer sells its
excimer lasers in Japan primarily through Cymer Japan. Cymer Korea, Cymer SEA,
Cymer Singapore and Cymer B.V. are field service offices for customers in those
regions. All significant intercompany balances have been eliminated in
consolidation.

         ACCOUNTING ESTIMATES - The preparation of financial statements in
conformity with generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results may differ from those estimates.

         UNAUDITED INTERIM FINANCIAL DATA - In the opinion of management, the
unaudited consolidated financial statements for the interim periods presented
reflect all adjustments, consisting of only normal recurring accruals, necessary
for a fair presentation of the financial position and results of operations as
of and for such periods indicated. These consolidated financial statements and
notes thereto should be read in conjunction with the consolidated financial
statements and notes thereto included in Cymer's Annual Report on Form 10-K
(including items incorporated by reference therein) for the year ended December
31, 1999. Results for the interim periods presented herein are not necessarily
indicative of results which may be reported for any other interim period or for
the entire fiscal year.


2.   EARNINGS PER SHARE

         EARNINGS PER SHARE - Basic Earnings Per Share ("EPS") excludes dilution
and is computed by dividing net income or loss attributable to common
stockholders by the weighted-average of common shares outstanding for the
period. Diluted EPS reflects the potential dilution that could occur if
securities or other contracts to issue common stock (convertible preferred
stock, warrants to purchase common stock and common stock options using the
treasury stock method) were exercised or converted into common stock. Potential
common shares in the diluted EPS computation are excluded in net loss periods as
their effect would be antidilutive.


                                       7
<PAGE>

<TABLE>
<CAPTION>
                                                             THREE MONTHS ENDED             SIX MONTHS ENDED
                                                                  JUNE 30,                      JUNE 30,
                                                         ---------------------------    --------------------------
                                                            1999            2000           1999           2000
                                                                 (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

<S>                                                      <C>             <C>           <C>             <C>
Net income (loss)                                           $(1,489)        $15,275      $ (3,787)        $25,450
                                                         ============    ===========    ===========    ===========

Basic earnings (loss) per share                             $ (0.05)        $  0.53      $  (0.14)        $  0.88
                                                         ============    ===========    ===========    ===========
Basic weighted average common shares outstanding             27,795          29,065        27,592          28,888

Effect of dilutive securities:
   Warrants                                                       -              33             -              34
   Options                                                        -           1,647             -           2,079
                                                         ------------    -----------    -----------    -----------
Diluted weighted average common and potential
   common shares outstanding                                 27,795          30,745        27,592          31,001
                                                         ============    ===========    ===========    ===========
Diluted earnings (loss) per share                           $ (0.05)        $  0.50      $  (0.14)        $  0.82
                                                         ============    ===========    ===========    ===========
</TABLE>

       For the three months ended June 30, 1999 and 2000, weighted average
options and warrants to purchase 2,901,000 and 283,000 shares of common stock,
respectively, were outstanding but not included in the computation of diluted
earnings per share as their effect was anti-dilutive. In addition, for the three
months ended June 30, 1999 and 2000, potential common shares attributable to
convertible subordinated notes of 3,670,213 and 3,666,703, respectively, were
not included in the calculation of diluted earnings per share as they were also
anti-dilutive.

       For the six months ended June 30, 1999 and 2000, weighted average options
and warrants to purchase 987,000 and 69,000 shares of common stock,
respectively, were outstanding but not included in the computation of earnings
per share as their effect was anti-dilutive. In addition, for the six months
ended June 30, 1999 and 2000, potential common shares attributable to
convertible subordinated notes of 3,670,213 and 3,666,703, respectively, were
not included in the calculation of diluted earnings per share as they were also
anti-dilutive.

3.   BALANCE SHEET DETAILS

<TABLE>
<CAPTION>
                                                          DECEMBER 31,   JUNE 30,
                                                              1999        2000
                                                           ----------  ---------
                                                                (IN THOUSANDS)
<S>                                                        <C>          <C>
INVENTORIES:
   Raw materials ....................                      $ 16,199    $ 17,242
   Work-in-progress .................                        18,661      25,052
   Finished goods ...................                        28,849      37,184
                                                           --------    --------
                                                             63,709      79,478
   Allowance for excess and obsolete                        (12,300)    (13,500)
                                                           --------    --------
   Total ............................                      $ 51,409    $ 65,978
                                                           ========    ========

ACCRUED AND OTHER LIABILITIES:
   Warranty and installation reserves                      $ 24,600    $ 32,500
   Payroll and payroll related ......                        11,952      11,050
   Interest .........................                        11,371      13,169
   Other ............................                         4,369       4,562
                                                           ========    ========
   Total ............................                      $ 52,292    $ 61,281
                                                           ========    ========
</TABLE>


                                       8
<PAGE>

4.   REPORTING COMPREHENSIVE INCOME

        The accumulated balance of other comprehensive income (loss) is
disclosed as a separate component of stockholders' equity. For Cymer,
comprehensive income includes foreign currency translation adjustments and
unrealized holding gains and losses on available-for-sale securities, which are
recorded on short-term and long-term investments in the accompanying
consolidated balance sheet.

     The following table summarizes the change in each component of accumulated
other comprehensive loss for the periods ended December 31, 1999 and June 30,
2000:

<TABLE>
<CAPTION>
                                                                          Total unrealized
                                                                         gains (losses) on          Accumulated
                                                     Translation         available-for-sale            other
                                                     adjustment,            investments,         comprehensive
                                                     net of tax              net of tax            income (loss)
                                                   ----------------     ---------------------    ------------------

<S>                                               <C>                     <C>                    <C>
 January 1, 1999            Balance                       $(1,862)                    $ 235               $(1,627)
                            Period net change              (1,719)                     (274)               (1,993)
                                                   ----------------     ---------------------    ------------------
 December 31, 1999          Balance                        (3,581)                      (39)               (3,620)
                            Period net change               1,473                        37                 1,510
                                                   ================     =====================    ==================
 June 30, 2000              Balance                       $(2,108)                    $  (2)              $(2,110)
                                                   ================     =====================    ==================
</TABLE>

5.   CLASS ACTION LAWSUITS

         Cymer has been named as a defendant in several putative shareholder
class action lawsuits which were filed in September and October, 1998 in the
U.S. District Court for the Southern District of California. Certain executive
officers and directors of Cymer are also named as defendants. The plaintiffs
purport to represent a class of all persons who purchased Cymer's Common Stock
between April 24, 1997 and September 26, 1997 (the "Class Period"). The
complaints allege claims under the federal securities laws. The plaintiffs
allege that Cymer and the other defendants made various material
misrepresentations and omissions during the Class Period. The complaints do not
specify the amount of damages sought. The complaints have been consolidated into
a single action and a class representative has been appointed by the court. A
consolidated amended complaint was filed in early August 1999. On November 5,
1999, Cymer and the other defendants filed a motion to dismiss the consolidated
amended claim for failure to state a cause of action. On April 1, 2000, the
court granted defendant's motion to dismiss with leave to amend the complaint by
the plaintiffs. The plaintiffs filed their second amended complaint on June 5,
2000. Cymer moved to dismiss the amended complaint on August 4, 2000. Cymer
believes it has meritorious defenses to the claims asserted and intends to
defend the action vigorously. Accordingly, no provision for any liability or
loss that may result from adjudication or settlement thereof has been made in
the accompanying consolidated financial statements.

6.   CONVERTIBLE SUBORDINATED NOTES

         In the first quarter of 2000, $165,000 of Cymer's subordinated notes
were converted to 3,510 shares of common stock.

7.   CONTINGENCIES

         Cymer's Japanese manufacturing partner and at least one of Cymer's
Japanese customers have been notified that Cymer's laser systems in Japan may
infringe certain Japanese patents held by another Japanese company. Cymer has
agreed to indemnify its Japanese manufacturing partner and its customers against
patent infringement claims under certain circumstances. Cymer believes, based
upon the advice of counsel, that Cymer's products do not infringe any valid
claim of the asserted patents or that it is entitled to prior user rights in
Japan.


                                       9
<PAGE>

       ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                            AND RESULTS OF OPERATIONS


         AN ASTERISK ("*") DENOTES A FORWARD-LOOKING STATEMENT REFLECTING
CURRENT EXPECTATIONS THAT INVOLVE RISKS AND UNCERTAINTIES. ACTUAL RESULTS MAY
DIFFER MATERIALLY FROM THOSE DISCUSSED IN SUCH FORWARD-LOOKING STATEMENTS, AND
STOCKHOLDERS OF CYMER, INC. (TOGETHER WITH ITS WHOLLY-OWNED AND MAJORITY-OWNED
SUBSIDIARIES, COLLECTIVELY, "CYMER") SHOULD CAREFULLY REVIEW THE CAUTIONARY
STATEMENTS SET FORTH IN THIS FORM 10Q, INCLUDING "RISK FACTORS" BEGINNING ON
PAGE 15 HEREOF. CYMER MAY FROM TIME TO TIME MAKE ADDITIONAL WRITTEN AND ORAL
FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS CONTAINED IN CYMER'S FILINGS
WITH THE SECURITIES AND EXCHANGE COMMISSION AND IN ITS REPORTS TO STOCKHOLDERS.
CYMER DOES NOT UNDERTAKE TO UPDATE ANY FORWARD-LOOKING STATEMENT THAT MAY BE
MADE FROM TIME TO TIME BY OR ON BEHALF OF CYMER.

RESULTS OF OPERATIONS

     The following table sets forth certain items in Cymer's consolidated
statements of operations as a percentage of total revenues for the periods
indicated:

<TABLE>
<CAPTION>
                                                         THREE MONTHS ENDED              SIX MONTHS ENDED
                                                              JUNE 30,                       JUNE 30,
                                                     ---------------------------    ---------------------------
                                                        1999            2000           1999           2000
<S>                                                    <C>             <C>            <C>            <C>
Revenues:
   Product sales                                         99.9%           99.5%          99.6%          99.7%
   Other                                                   .1              .5             .4             .3
                                                     ------------    -----------    -----------    ------------
            Total revenues                              100.0%          100.0%         100.0%         100.0%

Cost and expenses:
   Cost of product sales                                 65.4            50.9           67.7           53.8
   Research and development                              18.1            12.3           18.3           12.8
   Sales and marketing                                    8.0             5.5            8.4            5.1
   General and administrative                             7.3             5.5            7.1            5.6
                                                     ------------    -----------    -----------    ------------
            Total costs and expenses                     98.8            73.9          101.5           77.3
                                                     ------------    -----------    -----------    ------------

Operating income (loss)                                   1.2            26.1           (1.5)          22.7
Other expense - net                                      (2.3)            (.6)          (2.7)           (.6)
                                                     ------------    -----------    -----------    ------------

Income (loss) before provision for
   income taxes and minority interest                    (1.1)           25.5           (4.2)          22.1

Provision for income taxes                               (1.7)           (7.7)             -           (6.6)
Minority interest                                         (.6)            (.1)           (.3)           (.2)
                                                     ------------    -----------    -----------    ------------

Net income (loss)                                        (3.4%)          17.7%          (4.5%)         15.3%
                                                     ------------    -----------    -----------    ------------

Gross margin on product sales                            34.6%           49.1%          32.1%          46.0%
                                                     ------------    -----------    -----------    ------------
</TABLE>


                                       10
<PAGE>

THREE MONTHS ENDED JUNE 30, 1999 AND 2000

         REVENUES. Cymer's total revenues consist of product sales, which
include sales of laser systems, spare parts, service and training, and other
revenues, which primarily include revenues from funded development activities
performed for SEMATECH. Revenue from product sales is generally recognized at
the time of shipment, unless customer agreements contain inspection or other
conditions, in which case revenue is recognized at the time such conditions are
satisfied. Funded development contracts are accounted for on the
percentage-of-completion method based on the relationship of costs incurred to
total estimated costs, after giving effect to estimates of costs to complete the
development project.

         Product sales increased 98% from $43.4 million in the three months
ended June 30, 1999 to $85.8 million in the three months ended June 30, 2000,
primarily due to increased sales of DUV photolithography laser systems. Due to
the increase in Cymer's installed base of lasers, Cymer's revenues from spares,
replacement parts and services has increased and has become a larger component
of product sales. Funded development revenues increased from $31,000 for the
three months ended June 30, 1999 to $449,000 for the three months ended June 30,
2000, primarily due to the completion of various laser research projects
sponsored by customers and SEMATECH in 1999 compared to the addition of various
projects in 2000.

         Cymer's sales are generated primarily by shipments to customers in
Japan, the Netherlands, and the United States. Approximately 88%, 85% and 90% of
Cymer's sales in 1998, 1999 and the first six months of 2000, respectively, were
derived from customers outside the United States. Cymer maintains a wholly-owned
Japanese subsidiary which sells to Cymer's Japanese customers. Revenues from
Japanese customers, generated primarily by this subsidiary, accounted for 48%,
37% and 42% of revenues for 1998, 1999 and the first six months of 2000,
respectively. The activities of Cymer's Japanese subsidiary are limited to sales
and service of products purchased by the subsidiary from the parent corporation.
Costs of development and the majority of the production costs of Cymer's
products, including costs of shipment to Japan, are recorded on the books of the
parent company. Cymer anticipates that international sales will continue to
account for a significant portion of its net sales.*

         COST OF PRODUCT SALES. Cost of product sales includes direct material
and labor, warranty expenses, license fees, manufacturing and service overhead,
and foreign exchange gains and losses on foreign currency exchange contracts
associated with purchases of Cymer's products by the Japanese subsidiary for
resale under firm third-party sales commitments.

         Cost of product sales increased 54% from $28.4 million for the three
months ended June 30, 1999 to $43.6 million for the three months ended June 30,
2000 due to the increase in sales volume. The gross margin on these sales
increased from 34.6% for the three months ended June 30, 1999 to 49.1% for the
same three month period in 2000. This increase was primarily due to increased
product sales absorbing fixed manufacturing facility costs and reduced costs due
to improved efficiencies in some manufacturing processes.

         Net gains or losses from foreign currency exchange contracts are
included in cost of product sales in the consolidated statements of operations
as the related sales are recognized. Cymer recognized net gains on such
contracts of $122,000 and $657,000 for the three months ended June 30, 1999 and
2000, respectively.

         RESEARCH AND DEVELOPMENT. Research and development expenses include
costs of internally-funded and externally-funded projects as well as continuing
research support expenses which primarily include employee and material costs,
depreciation of equipment and other engineering related costs. Research and
development expenses increased 35% from $7.9 million for the three months ended
June 30, 1999 to $10.6 million for the three months ended June 30, 2000, due
primarily to increased product development efforts related to an increase in
projected product introductions. Research and development expenses in 1999
consisted of costs associated with the development of the Orion or ELS-6000
laser system. During the second quarter of 2000, the increased expenses reflect
the continued development efforts for the ELS-6000 laser system, as well as the
initial stages of development for the ELS-6010 laser and the


                                       11
<PAGE>

6000A series argon fluoride laser. As a percentage of total revenues, such
expenses decreased from 18.1% to 12.3% in the respective periods due to
substantially increased revenues.

         SALES AND MARKETING. Sales and marketing expenses include the
expenses of the sales, marketing and customer support staffs and other
marketing expenses. Sales and marketing expenses increased 37% from $3.5
million for the three months ended June 30, 1999 to $4.7 million for the
three months ended June 30, 2000 due primarily to increased staffing expenses
associated with the recruiting of senior marketing management as well as
increased travel expenses resulting from increased business operations. As a
percentage of total revenues, such expenses decreased from 8.0% to 5.5% in
the respective periods due to substantially increased revenues.

         GENERAL AND ADMINISTRATIVE. General and administrative expenses consist
primarily of management and administrative personnel costs, professional
services and administrative operating costs. General and administrative expenses
increased 49% from $3.2 million in the three months ended June 30, 1999 to $4.7
million for the three months ended June 30, 2000, due to continuing process
quality development efforts, including the implementation of a new Enterprise
Resource Planning ("ERP") system which is currently in process and the required
general and administrative support activities. As a percentage of total
revenues, such expenses decreased from 7.3% to 5.5% from period to period.

         OTHER INCOME (EXPENSE) - NET. Net other income (expense) consists
primarily of interest income and expense and foreign currency exchange gains and
losses associated with fluctuations in the value of the Japanese yen against the
United States dollar. Net other expense decreased from $1.0 million for the
three months ended June 30, 1999 to $506,000 for the three months ended June 30,
2000, primarily due to an increase in interest income associated with higher
market yields in 2000 on the investment of increased cash balances. Foreign
currency exchange gains totaled $161,000, interest income totaled $1.7 million
and interest expense totaled $2.8 million for the three months ended June 30,
1999, compared to an exchange loss of $37,000, interest income of $2.8 million,
$2.9 million in interest expense and other expense of $400,000.

         Cymer's results of operations are subject to fluctuations in the value
of the Japanese yen against the United States dollar. Sales by Cymer to its
Japanese subsidiary are denominated in dollars, and sales by the subsidiary to
customers in Japan are denominated in yen. Cymer's Japanese subsidiary manages
its exposure to such fluctuations by entering into foreign currency exchange
contracts to hedge its purchase commitments to Cymer. The gains or losses from
these contracts are recorded as a component of cost of product sales, while the
remaining foreign currency exposure is recorded as other income (expense) in the
consolidated statements of operations. Gains and losses resulting from foreign
currency translation are accumulated as a separate component of consolidated
stockholders' equity.

         INCOME TAX PROVISION. The tax provision of $758,000 reported for the
three months ended June 30, 1999 reflects an annual effective tax rate of 0%.
The provision for income taxes for the three months ended June 30, 2000 of
$6,600,000 reflects an annual effective tax rate of 30%. The annual effective
tax rates for both periods are less than the U.S. statutory rate of 35%
primarily as a result of permanent book/tax differences and tax credits.

SIX MONTHS ENDED JUNE 30, 1999 AND 2000

         REVENUES. Product sales increased 100% from $83.2 million for the
six months ended June 30, 1999 to $166.3 million in the six months ended June
30, 2000, primarily due to increased sales of DUV photolithography laser
systems. Due to the increase in Cymer's installed base of lasers, Cymer's
revenues from spares, replacement parts and services has increased and has
become a larger component of product sales. Funded development revenues
increased from $299,000 for the six months ended June 30, 1999 to $534,000
for the six months ended June 30, 2000, primarily due to the completion of
various laser research projects sponsored by customers and SEMATECH in 1999
compared to the addition of various projects in 2000.

                                       12
<PAGE>

         COST OF PRODUCT SALES. Cost of product sales increased 59% from $56.5
million for the six months ended June 30, 1999 to $89.8 million for the six
months ended June 30, 2000 due to the increase in sales volume. The gross margin
on these sales increased from 32.1% for the six months ended June 30, 1999 to
46.0% for the same six month period in 2000. This increase was primarily due to
increased product sales absorbing fixed manufacturing facility costs and reduced
costs due to improved efficiencies in some manufacturing processes.

         Net gains or losses from foreign currency exchange contracts are
included in cost of product sales in the consolidated statements of operations
as the related sales are recognized. Cymer recognized a net loss on such
contracts of $829,000 for the six months ended June 30, 1999 compared to a net
gain of $1.4 million for the six months ended June 30, 2000.

         RESEARCH AND DEVELOPMENT. Research and development expenses increased
40% from $15.3 million for the six months ended June 30, 1999 to $21.4 million
for the six months ended June 30, 2000, due primarily to increased product
development efforts related to an increase in projected product introductions.
Research and development expenses in 1999 consisted of costs associated with the
development of the Orion or ELS-6000 laser system. During the first half of
2000, the increased expenses reflect the continued development efforts for the
ELS-6000 laser system as well as ELS-6010 laser and argon fluoride laser
development. As a percentage of total revenues, such expenses decreased from
18.3% to 12.8% in the respective periods due to substantially increased
revenues.

         SALES AND MARKETING. Sales and marketing expenses increased 22% from
$7.0 million for the six months ended June 30, 1999 to $8.5 million for the six
months ended June 30, 2000 due primarily to increased staffing expenses,
including recruiting costs due to expanded operations in the areas of product
marketing and sales administration. As a percentage of total revenues, such
expenses decreased from 8.4% to 5.1% in the respective periods due to
substantially increased revenues.

         GENERAL AND ADMINISTRATIVE. General and administrative expenses
increased 56% from $6.0 million in the six months ended June 30, 1999 to $9.3
million for the six months ended June 30, 2000, due to the continuing process
quality development efforts, including the implementation of a new Enterprise
Resource Planning ("ERP") system which is currently in process and the required
general and administrative support activities. As a percentage of total
revenues, such expenses decreased from 7.1% to 5.6% from period to period.

         OTHER INCOME (EXPENSE) - NET. Net other expense decreased from $2.2
million for the six months ended June 30, 1999 to $1.0 million for the six
months ended June 30, 2000, primarily due to the increase in interest income
associated with higher market yields in 2000 on the investment of increased cash
balances. Foreign currency exchange losses totaled $74,000, interest income
totaled $3.4 million and interest expense totaled $5.6 million for the six
months ended June 30, 1999, compared to an exchange loss of $20,000, interest
income of $5.2 million, $5.8 million in interest expense and other expense of
$400,000.

         Cymer's results of operations are subject to fluctuations in the value
of the Japanese yen against the United States dollar. Sales by Cymer to its
Japanese subsidiary are denominated in dollars, and sales by the subsidiary to
customers in Japan are denominated in yen. Cymer's Japanese subsidiary manages
its exposure to such fluctuations by entering into foreign currency exchange
contracts to hedge its purchase commitments to Cymer. The gains or losses from
these contracts are recorded as a component of cost of product sales, while the
remaining foreign currency exposure is recorded as other income (expense) in the
consolidated statements of operations. Gains and losses resulting from foreign
currency translation are accumulated as a separate component of consolidated
stockholders' equity.

         INCOME TAX PROVISION. The tax provision of $0 reported for the six
months ended June 30, 1999 reflects an annual effective tax rate of 0%. The
provision for income taxes for the six months ended June 30, 2000 of $11,048,000
reflects an annual effective tax rate of 30%. The annual effective tax rates for
both periods are less than the U.S. statutory rate of 35% primarily as a result
of permanent book/tax differences and tax credits.


                                       13
<PAGE>

LIQUIDITY AND CAPITAL RESOURCES

          Since its initial public offering and a second public offering, both
in 1996, Cymer has funded its operations primarily through a convertible
subordinated note offering on August 6, 1997, which generated $167.3 million in
net proceeds, and from bank borrowings, cash flow from operations and the
proceeds from employee stock option exercises. As of June 30, 2000, Cymer had
approximately $92.9 million in cash and cash equivalents, $105.4 million in
short-term investments, $3.5 million in long-term investments, $249.1 million in
working capital and $17.7 million in bank debt.

         Net cash provided by operating activities was approximately $4.3
million and $24.3 million for the six months ended June 30, 1999 and 2000,
respectively. The increase in cash was due primarily to Cymer's improved
profitable operations. For the six months ended June 30, 1999, a net loss of
$3.8 million was recorded versus net income of $25.5 million for the six months
ended June 30, 2000. In addition, increases in inventory, accounts receivable,
and income taxes payable resulted from increased revenues and bookings during
the six months ended June 30, 2000 and were offset by increased accrued and
other liabilities during the same period.

         Net cash provided by investing activities was approximately $9.5
million for the six months ended June 30, 1999 as compared to $17.7 million used
in investing activities for the six months ended June 30, 2000. The net cash
provided by investing activities during the first six months of 1999 primarily
reflects the timing of short and long term investments maturing and being
reinvested during the period, offset by property acquisitions to accommodate
business expansion and focus. For the first six months of 2000, the cash used
primarily reflects the continued investment in property acquisitions to
accommodate the increased business activity, such as the construction of an
additional facility at the San Diego, California location, as well as the
implementation of a new ERP system. In addition, $1.1 million in cash was used
for the acquisition of the minority shareholder interest in Cymer's Taiwan
subsidiary during the first six months of 2000.

         Net cash provided by financing activities was approximately $7.4
million and $7.0 million for the six months ended June 30, 1999 and 2000,
respectively. The net cash provided by financing activities for the six months
ended June 30, 1999 was primarily attributable to $4.8 million in bank
borrowings in Japan and the receipt of $3.0 million upon the issuance of common
stock due to the exercising of stock options by Cymer employees. For the period
ended June 30, 2000, the cash provided was attributable to the receipt of $7.5
million upon issuance of common stock due to employee stock option exercises
offset by dividends paid to minority shareholder of foreign subsidiary and
payments on capital lease obligations.

         Cymer requires substantial working capital to fund its business,
particularly to finance inventories and accounts receivable and for capital
expenditures. Cymer's future capital requirements will depend on many factors,
including the rate of Cymer's manufacturing expansion, the timing and extent of
spending to support product development efforts and expansion of sales and
marketing and field service and support, the timing of introductions of new
products and enhancements to existing products, and overall industry conditions.
Cymer believes that it has sufficient working capital and available bank credit
to sustain operations and provide for the future expansion of its business
during 2000.*

RECENT ACCOUNTING PRONOUNCEMENTS

         In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivative
Instruments and Hedging Activities." SFAS No. 133 establishes accounting and
reporting standards for derivative instruments and for hedging activities. The
new standard, as amended, will become effective for Cymer for the first quarter
of 2001. Interim reporting for this standard will be required. Cymer has not yet
assessed the effect of this standard on Cymer's current reporting and
disclosures.


                                       14
<PAGE>

RISK FACTORS

LIKELY FLUCTUATIONS IN OPERATING RESULTS

         CERTAIN FACTORS CAUSING FLUCTUATIONS

         Cymer's operating results have in the past fluctuated and are likely in
the future to fluctuate significantly. These fluctuations depend on a variety of
factors which may include:

         -        the demand for semiconductors in general and, in particular,
                  for leading edge devices with smaller circuit geometries;

         -        the rate at which semiconductor manufacturers take delivery of
                  photolithography tools from Cymer's customers and rate at
                  which those customers take delivery of lightsources from
                  Cymer;

         -        cyclicality in the market for semiconductor manufacturing
                  equipment;

         -        the timing and size of orders from Cymer's small base of
                  customers;

         -        the ability of Cymer to manufacture, test and deliver laser
                  systems in a timely and cost effective manner;

         -        the mix of laser models, replacement parts and service
                  revenues;

         -        the ability of Cymer's competitors to obtain orders from
                  Cymer's customers;

         -        the entry of new competitors into the market for DUV
                  photolithography illumination sources;

         -        the ability of Cymer to manage its costs as it supplies its
                  products in higher volumes and multiple different models; and

         -        Cymer's ability to effectively manage its exposure to foreign
                  currency exchange rate fluctuations, principally with respect
                  to the Japanese yen (in which sales by Cymer's Japanese
                  subsidiary are denominated).

In addition, as customers become more efficient at integrating Cymer's lasers
into their photolithography tools, reductions in customer laser inventories may
affect Cymer's operating results.

         TIMING OF REVENUE RECOGNITION

         Cymer has historically derived a substantial portion of its quarterly
and annual revenues from the sale of a relatively small number of systems. As a
result, the precise timing of the recognition of revenue from an order for a
small number of systems can have a significant impact on Cymer's total revenues
and operating results for a particular period. If customers cancel or reschedule
orders for a small number of systems or if Cymer cannot fill orders in time to
recognize revenue during a particular period, this could adversely affect
Cymer's operating results for that period. For example, unanticipated
manufacturing, testing, shipping or product acceptance delays could cause such
cancellations, rescheduling or inability to fill orders promptly.

         FIXED EXPENSES

         Cymer's expense levels are based, in large part, on Cymer's
expectations as to future revenues. Therefore, Cymer's expenses are relatively
fixed in the short term. If revenue levels fall below expectations, this would
disproportionately and adversely affect net income. Cymer cannot forecast the
impact of these and other factors on its revenues and operating results in any
future period with any degree of certainty.

         SEMICONDUCTOR MANUFACTURER DEMAND

         Cymer believes that semiconductor manufacturers are currently growing
capacity and developing capability for production and pilot production of 0.25um
to 0.18um and below devices.


                                       15
<PAGE>

Cymer also believes that the efforts to develop such capacity and/or capability
are driving present demand for its laser systems for DUV photolithography tools.
Once semiconductor manufacturers have acquired such capacity and/or capability,
their demand for Cymer's DUV photolithography tools will depend on whether they
want to expand their capacity further to manufacture such devices. This will in
turn depend on whether their sales forecasts and manufacturing process yields
justify such an investment. Cymer currently expects that demand for its DUV
laser systems will depend on such demand and process development constraints of
the semiconductor manufacturers.

         INDUSTRY CONDITIONS

         Cymer is expanding certain aspects of its operations in response to
improvements in industry conditions. Should continued improvements not
materialize, the planned increases in spending may negatively impact profitable
operations.

         Due to the foregoing, as well as other unanticipated factors, Cymer's
operating results will likely fall below the expectations of public market
analysts or investors in some future quarter or quarters. Such failure to meet
operating result expectations would materially adversely affect the price of
Cymer's Common Stock.

DEPENDENCE ON SEMICONDUCTOR INDUSTRY

          Cymer derives substantially all of its revenues from photolithography
tool manufacturers. Photolithography tool manufacturers depend in turn on the
demand for their products from semiconductor manufacturers. Semiconductor
manufacturers depend on the demand from manufacturers of end-products or systems
that use semiconductors. The semiconductor industry is highly cyclical and has
historically experienced periodic and significant downturns. These downturns
have often had a severe effect on the demand for semiconductor manufacturing
equipment, including photolithography tools. Cymer believes that downturns in
the semiconductor manufacturing industry will periodically occur, resulting in
periodic decreases in demand for semiconductor manufacturing equipment. In
addition, Cymer believes that in a future downturn Cymer's need to continue
investment in research and development, and to maintain extensive ongoing
customer service and support capability, will constrain its ability to reduce
expenses. Accordingly, downturns in the semiconductor industry would likely have
a material adverse effect on Cymer's business, financial condition and results
of operations.

DEPENDENCE ON SMALL NUMBER OF CUSTOMERS

         A small number of manufacturers of DUV photolithography tools
constitute Cymer's primary customer base. Three large firms, ASM Lithography,
Canon and Nikon dominate the photolithography tool business. Collectively, they
accounted for approximately 88%, 74% and 77% of Cymer's total revenues in 1998,
1999, and the six months ended June 30, 2000, respectively. Individually, sales
to ASM Lithography, Canon and Nikon accounted for approximately 33%, 17% and
24%, respectively, of total revenues in 1999 and 32%, 16% and 29%, respectively,
of total revenues for the six months ended June 30, 2000. Cymer expects that
sales of its systems to these customers will continue to account for a
substantial majority of its revenues in the foreseeable future. None of Cymer's
customers are obligated to purchase a minimum number of Cymer's products. The
loss of any significant business from any one of these customers, a significant
reduction in orders from any one of these customers or production problems for
any one of these customers that cause a slow down in Cymer's deliveries, would
have a material adverse effect on Cymer's business, financial condition and
results of operations. Reductions caused by changes in a customer's competitive
position, a decision to purchase illumination sources from other suppliers, or
economic conditions in the semiconductor and photolithography tool industries,
could all cause such a loss of business or reduction in orders.


                                       16
<PAGE>

NEED TO MANAGE A CHANGING BUSINESS

         In recent years, in response to business cycles in the semiconductor
industry, Cymer has sharply expanded and contracted the scope of its operations
and the number of employees in most of its functional areas. As of June 30,
2000, Cymer had 832 employees. Cymer has substantially expanded its facilities
and manufacturing capacity. For example, since December 31, 1996 Cymer has
occupied three additional buildings covering approximately 187,000 square feet.
In a cyclical environment of dramatic growth or contraction, Cymer will need:

         -     to continue close management of these areas, and
         -     to improve its management, operational and financial systems,
               including
                  -        accounting and other internal management systems,
                  -        quality control,
                  -        delivery,
                  -        field service and customer support capabilities and,
                  -        changing sales and marketing channels.

Cymer must also effectively manage its inventory levels, including assessing and
managing excess and obsolete inventories associated with the changing
environment and new product introductions. Cymer will need to attract, train,
retain and manage key technical personnel in order to support Cymer's growth
and/or contraction. Cymer will also need to manage effectively its international
operations, including:

         -        the operations of its subsidiaries in Japan, Korea, Taiwan,
                  Singapore and The Netherlands,

         -        its field service and support presence in Asia and Europe and

         -        its relationship with Seiko as a manufacturer of its
                  photolithography lasers.

Cymer must also effect timely deliveries of its products and maintain the
product quality and reliability required by its customers. Any failure to
effectively manage Cymer's growth or contraction would materially adversely
affect Cymer's financial condition and results of operations.

RISKS ASSOCIATED WITH IMPLEMENTING A NEW ENTERPRISE RESOURCE PLANNING SYSTEM

Cymer is in the process of implementing a new corporate wide enterprise resource
planning ("ERP") system to replace its current ERP system. Cymer has scheduled
implementation of the new ERP system and training of personnel to use the system
to be completed during the year 2000.* The implementation of a new ERP system
requires full commitment of management and the dedication and utilization of
significant internal as well as external resources in managing the project,
process redesigns, system integration and employee training. Historically, many
companies have experienced difficulties in implementing ERP systems. These
difficulties range from cost overruns, push-outs of implementation deadlines,
process and operations gridlock, failure to execute operating plans, including
inability to ship products for revenue, and abandonment of the effort
altogether. Cymer must effectively manage its planning and execution of the
implementation of the system and the training of personnel throughout the
Company. Any failure to effectively manage Cymer's efforts or process and
operations designs would materially adversely affect Cymer's financial condition
and results of operations.

RAPID TECHNOLOGICAL CHANGE; NEW PRODUCT INTRODUCTIONS

         Semiconductor manufacturing equipment and processes are subject to
rapid technological change. Cymer believes that its future success will depend
in part upon its ability to:

         -        continue to enhance its excimer laser products and their
                  process capabilities, an
         -        develop and manufacture new products with improved
                  capabilities.


                                       17
<PAGE>

In order to enhance and improve its products and develop new products, among
other things, Cymer must work closely with its customers, particularly in the
product development stage, to integrate its lasers with its customers'
photolithography tools. Future technologies, such as EUV and scalpel processes,
might render Cymer's excimer laser products obsolete. Further, Cymer might not
be able to develop and introduce new products or enhancements to its existing
products and processes in a timely or cost effective manner that satisfy
customer needs or achieve market acceptance. The failure to do so could
materially adversely affect Cymer's business, financial condition and results of
operations.

DEPENDENCE ON KEY SUPPLIERS

           Cymer obtains certain of the components and subassemblies included in
its products from a single supplier or a limited group of suppliers. In
particular, there are no alternative sources for certain of such components and
subassemblies, including certain optical components used in Cymer's lasers. In
addition, Cymer is increasingly outsourcing the manufacture of various
subassemblies. To date Cymer has been able to obtain adequate supplies of the
components and subassemblies in a timely manner from existing sources. However,
due to the nature of Cymer's product development requirements, key suppliers
often need to rapidly advance their own technologies in order to support Cymer's
new product introduction schedule. These suppliers may or may not be able to
satisfy Cymer's schedule requirements in providing new modules and subassemblies
to Cymer. If Cymer cannot obtain sufficient quantities of such materials,
components or subassemblies, or if such items do not meet Cymer's quality
standards, delays or reductions in product shipments could have a material
adverse effect on Cymer's business, financial condition and results of
operations.

COMPETITION

         LAMBDA-PHYSIK, KOMATSU AND USHIO

         Cymer currently has three significant competitors in the market for
excimer laser systems for photolithography applications:

         -     Lambda-Physik,
         -     Komatsu, Ltd. and
         -     Ushio.

On July 10, 2000 Ushio and Komatsu announced the combination of their excimer
laser business into a joint venture to be known as Gigaphoton Inc.

All of these companies:

         -        are larger than Cymer,
         -        have access to greater financial, technical and other
                  resources than does Cymer, and
         -        are located in closer proximity to Cymer's customers than is
                  Cymer.

Cymer believes that Lambda-Physik and Komatsu are aggressively seeking to gain
larger positions in this market. Cymer believes that its customers have each
purchased products offered by these competitors and that its customers have
qualified competitors' lasers for use with their products. Cymer believes that
Komatsu in particular has been qualified for production use by chipmakers in
Japan and elsewhere. Cymer also believes that Lambda-Physik has been qualified
for production use by chipmakers in the U.S. Cymer could lose market share and
its growth could slow or even decline as competitors gain market acceptance.


                                       18
<PAGE>

         OTHER TECHNOLOGIES

         In the future, Cymer will likely experience competition from other
technologies, such as EUV and scalpel processes. To remain competitive, Cymer
believes that it will need to:

         -        manufacture and deliver products to customers on a timely
                  basis and without significant defects, and
         -        maintain a high level of investment in research and
                  development and in sales and marketing.

Cymer might not have sufficient resources to continue to make the investments
necessary to maintain its competitive position.

         SMALL AND IMMATURE MARKET FOR EXCIMER LASERS

         The market for excimer lasers is still small and immature. Larger
competitors with substantially greater financial resources, including other
manufacturers of industrial lasers, might attempt to enter the market.

         Cymer might not remain competitive. A failure to remain competitive
would have a material adverse effect on Cymer's business, financial condition
and results of operations.

DEPENDENCE ON KEY PERSONNEL

         Cymer is highly dependent on the services of a number of key employees
in various areas, including:

         -        engineering,

         -        research and development,

         -        sales and marketing, and

         -        manufacturing.

In particular, there are a limited number of experts in excimer laser
technology. There is intense competition for such personnel, as well as for the
highly-skilled hardware and software engineers Cymer requires. Cymer has in the
past experienced, and continues to experience, difficulty in hiring personnel,
including experts in excimer laser technology. Cymer believes that, to a large
extent, its future success will depend upon:

         -        the continued services of its engineering, research and
                  development, sales and marketing and manufacturing and service
                  personnel, and

         -        its ability to attract, train and retain highly skilled
                  personnel in each of these areas.

Cymer does not have employment agreements with most of its employees, and Cymer
might not be able to retain its key employees. The failure of Cymer to hire,
train and retain such personnel could have a material adverse effect on Cymer's
business, financial condition and results of operations.

DEPENDENCE ON SINGLE PRODUCT LINE

         Cymer's only product line is excimer lasers ("KrF, ArF and F2 laser
systems"). The primary market for excimer lasers is for use in DUV
photolithography equipment for manufacturing deep-submicron semiconductor
devices. Demand for Cymer's products will depend in part on the rate at which
semiconductor manufacturers adopt excimer lasers as the illumination source for
their photolithography tools.


                                       19
<PAGE>

 Impediments to such adoption include:

         -        instability of photoresists used in advanced DUV
                  photolithography and

         -        potential shortages of specialized materials used in DUV
                  optics.

There can be no assurance that such impediments can or will be overcome. In any
event, such impediments may materially reduce the demand for Cymer's products.
Further, if Cymer's customers experience reduced demand for DUV photolithography
tools, or if Cymer's competitors are successful in obtaining significant orders
from such customers, Cymer's financial condition and results of operations would
be materially adversely affected.

DISRUPTION OF ELECTRIC SERVICE

         California and particularly San Diego County, the location of Cymer's
headquarters and primary manufacturing facility, has been experiencing unusually
hot and humid weather. This has caused Cymer's electric utility supplier to
notify the company that it could be subject to blackouts of electric power.
While Cymer has some back up power capability, any prolonged blackout or series
of periodic blackouts could disrupt Cymer's production schedule. Any material
disruption of electric service would have an adverse impact upon Cymer's
financial performance.

RISK OF EXCESSIVE INVENTORY BUILDUPS BY PHOTOLITHOGRAPHY TOOL MANUFACTURERS

         Photolithography tool manufacturers constitute substantially all of
Cymer's customers. Photolithography tool manufacturers sell their systems in
turn to semiconductor manufacturers. Market conditions in the industry can cause
Cymer's customers to expand or reduce their orders for new laser systems as they
try to manage their inventories to appropriate levels which better reflect their
expected sales forecasts. Cymer is working with its customers to better
understand end user demand for DUV photolithography tools. However, there can be
no assurance that Cymer will be successful in this regard, or that its customers
will not build excessive laser inventories. Excessive customer laser inventories
could result in a material decline in Cymer's revenues and operating results in
future periods as such inventories are brought into balance.

PRODUCTION USE OF EXCIMER LASERS

         Cymer's products might not meet production specifications or cost of
operation requirements over time when subjected to prolonged and intense use in
volume production in semiconductor manufacturing processes. If any semiconductor
manufacturer cannot successfully achieve or sustain volume production using
Cymer's lasers, Cymer's reputation with semiconductor manufacturers or the
limited number of photolithography tool manufacturers could be damaged. This
would have a material adverse effect on Cymer's business, financial condition
and results of operations.

MAINTENANCE OF FIELD SERVICE AND SUPPORT ORGANIZATION

         Cymer believes that the need to provide fast and responsive service to
the semiconductor manufacturers using its lasers is critical. Cymer cannot
depend solely on its direct customers to provide this specialized service.
Therefore, Cymer believes it is essential to maintain through its own personnel,
a rapid response capability to service its lasers throughout the world.
Accordingly, Cymer has an ongoing effort to continuously develop its direct
support infrastructure in the United States, Japan, Europe, Korea, Singapore,
Taiwan and Southeast Asia. This task entails recruiting and training qualified
field service personnel and maintaining effective and highly trained
organizations that can provide service to customers in various countries in
their assigned regions. Cymer has historically experienced difficulties in
effectively training field service personnel. Additionally, field service
personnel often experience high turnover. Cymer might not be able to attract and
train qualified personnel to maintain these operations successfully. Further,
the costs


                                       20
<PAGE>

of such operations might be excessive. A failure to implement this plan
effectively could have a material adverse effect on Cymer's business, financial
condition and results of operations.

UNCERTAINTY REGARDING PATENTS AND PROTECTION OF PROPRIETARY TECHNOLOGY

         CYMER PATENTS

         Cymer believes that the success of its business depends more on such
factors as the technical expertise of its employees, as well as their innovative
skills and marketing and customer relations ability, than on patents,
copyrights, trade secrets and other intellectual property rights. Nevertheless,
the success of Cymer may depend in part on patents. As of June 30, 2000, Cymer
owned 82 United States patents covering certain aspects of technology associated
with excimer lasers. Such patents will expire at various times during the period
from January 2008 to May 2019. As of June 30, 2000, Cymer had also applied for
65 additional patents in the United States, 3 of which have been allowed. As of
June 30, 2000, Cymer owned 50 foreign patents and had filed 224 patent
applications pending in various foreign countries.

         Cymer's pending patent applications and any future applications might
not be approved. Cymer's patents might not provide Cymer with competitive
advantages. Third parties might challenge Cymer's patents. In addition, third
parties' patents might have an adverse effect on Cymer's ability to do business.
In this regard, due to cost constraints, Cymer did not begin filing for patents
in Japan or other countries with respect to inventions covered by its United
States patents and patent applications until 1993. Therefore, Cymer lost the
right to seek foreign patent protection for certain of its inventions.
Additionally, because foreign patents may afford less protection under foreign
law than is available under United States patent law, any such patents issued to
Cymer might not adequately protect Cymer's technology in a given foreign
jurisdiction. Furthermore, third parties might independently develop similar
products, duplicate Cymer's products or, to the extent patents are issued to
Cymer, design around the patents issued to Cymer.

         COMPETITIVE PATENTS

         Others may have filed and in the future may file patent applications
that are similar or identical to those of Cymer. To determine the priority of
inventions, Cymer may have to participate in interference proceedings declared
by the United States Patent and Trademark Office. Such interference proceedings
could result in substantial cost to Cymer. Such third party patent applications
might have priority over patent applications filed by Cymer.

         OTHER FORMS OF PROTECTION

         Cymer also relies upon:

         -        trade secret protection,
         -        employee nondisclosure agreements,
         -        third-party nondisclosure agreements, and
         -        other intellectual property protection methods

to protect its confidential and proprietary information. Despite these efforts,
third parties might:

         -        independently develop substantially equivalent proprietary
                  information and techniques,
         -        otherwise gain access to Cymer's trade secrets, or
         -        disclose such technology.

Cymer might not be able to meaningfully protect its trade secrets.


                                       21
<PAGE>

         POSSIBLE CLAIMS TO OWNERSHIP OF CYMER'S INTELLECTUAL PROPERTY

         Cymer has in the past funded a significant portion of its research and
development expenses from outside research and development revenues. Cymer has
received such revenues from photolithography tool manufacturers and from
SEMATECH, a semiconductor industry consortium, in connection with the design and
development of specific products. Cymer currently funds a small portion of its
development expenses through SEMATECH. Although Cymer's arrangements with
photolithography tool manufacturers and SEMATECH seek to clarify the ownership
of the intellectual property arising from research and development services
performed by Cymer, disputes over the ownership or rights to use or market such
intellectual property might arise between Cymer and such parties. Any such
dispute could result in restrictions on Cymer's ability to market its products
and could have a material adverse effect on Cymer's business, financial
condition and results of operations.

         PATENT INFRINGEMENT

         Third parties have in the past notified, and may in the future notify,
Cymer that it may be infringing intellectual property rights of others.
Conversely, Cymer has in the past notified, and may in the future notify, third
parties that they may be infringing Cymer's intellectual property rights.

         Specifically, Cymer has engaged in discussions with one of its
competitors, Komatsu, with respect to certain of Komatsu's Japanese patents, in
the course of which Komatsu has also identified to Cymer a number of additional
Japanese and U.S. patents that Komatsu asserts may be infringed by Cymer or by
Cymer's Japanese manufacturing partner, Seiko. Komatsu has also notified one of
Cymer's integrator customers, Nikon, of its belief that Cymer's lasers infringe
several of Komatsu's Japanese and U.S. patents. Cymer, in consultation with
Japanese patent counsel, has initiated oppositions to certain Komatsu Japanese
patents and patent applications in the Japanese Patent Office. Some of these
oppositions have been dismissed by the Japanese Patent Office. Litigation might
ensue with respect to the Komatsu Japanese patents or Komatsu U.S. patents.
Also, Komatsu might assert infringement claims under other or additional
patents. Komatsu has notified Seiko that Komatsu intends to enforce its rights
under the Komatsu Japanese patents against Seiko if Seiko engages in
manufacturing activities for Cymer. In connection with its manufacturing
agreement with Seiko, Cymer has agreed to indemnify Seiko against such claims
under certain circumstances. Cymer and Seiko might not ultimately prevail in any
such litigation.

         Cymer has notified its competitors and others of Cymer's United States
patent portfolio. Cymer has specifically asserted certain of its U.S. patents
against Komatsu when informed that Komatsu lasers might be integrated into
steppers intended for shipment into the U.S. Cymer and Komatsu have engaged in
discussions with regard to each party's claims. Those discussions might not be
successful and litigation could result. Attorneys representing Komatsu are
currently challenging one of Cymer's U.S. patents in the U.S. Patent Office.
Cymer has also been engaged in patent discussions with another competitor,
Lambda-Physik, concerning allegations by each party against the other of
possible patent infringement. These discussions also might not be successful and
litigation could result.

         Any patent litigation initiated by Cymer, or initiated by Cymer's
competitors against Cymer, would, at a minimum, be costly. Litigation could also
divert the efforts and attention of Cymer's management and technical personnel.
Both could have a material adverse effect on Cymer's business, financial
condition and results of operations. Furthermore, in the future other third
parties might assert other infringement claims, and customers and end users of
Cymer's products might assert other claims for indemnification resulting from
infringement claims. Such assertions, if proven to be true, might materially
adversely affect Cymer's business, financial condition and results of
operations. If any such claims are asserted against Cymer, Cymer may seek to
obtain a license under the third party's intellectual property rights. However,
such a license might not be


                                       22
<PAGE>

available on reasonable terms or at all. Cymer could decide, in the alternative,
to resort to litigation to challenge such claims or to design around the
patented technology. Such actions could be costly and would divert the efforts
and attention of Cymer's management and technical personnel, which would
materially adversely affect Cymer's business, financial condition and results of
operations.

         TRADEMARK

         Cymer has registered the trademark CYMER in the United States and
certain other countries and is seeking additional registrations of other
trademarks including "Insist on Cymer" in the United States and in certain other
countries. Cymer uses these and a variety of other marks in its advertisements
and other business activities around the world. Based on the use of these or
other marks, Cymer might be subjected to actions for trademark infringement,
which could be costly to defend. If a challenge to a mark were to be successful,
Cymer might be required to cease use of the mark and, potentially, to pay
damages.

RISKS ASSOCIATED WITH MANUFACTURING IN JAPAN

         Cymer has qualified Seiko of Japan as a contract manufacturer of its
photolithography lasers. Komatsu, a competitor of Cymer, has advised Seiko that
certain aspects of Cymer's lasers might infringe certain patents that have been
issued to Komatsu in Japan. Komatsu has advised Seiko it intends to enforce its
rights under such patents against Seiko if Seiko engages in manufacturing
activities for Cymer. In the event that, notwithstanding its manufacturing
agreement with Cymer, Seiko should determine not to continue manufacturing
Cymer's products until resolution of the matter with Komatsu, Cymer's ability to
meet any heavy demand for its products could be materially adversely affected.
See -- "Uncertainty Regarding Patents and Protection of Proprietary Technology."

RISKS OF INTERNATIONAL SALES AND OPERATIONS

         SIGNIFICANT INTERNATIONAL TRADE

         Cymer derived approximately 88%, 85% and 90% of its revenues in 1998,
1999 and the six months ended June 30, 2000, respectively, from customers
located outside the United States. Because a significant majority of Cymer's
principal customers are located in other countries, particularly Asia, Cymer
anticipates that international sales will continue to account for a significant
portion of its revenues.* In order to support its overseas customers, Cymer:

         -        maintains subsidiaries in Japan, Korea, Taiwan, Singapore and
                  the Netherlands,
         -        is further developing its field service and support operations
                  worldwide, and
         -        will continue to work with Seiko as a manufacturer of its
                  products in Japan.*

Cymer might not be able to manage these operations effectively. Cymer's
investment in these activities might not enable it to compete successfully in
international markets or to meet the service and support needs of its customers.
Additionally, a significant portion of Cymer's sales and operations could be
subject to certain risks, including:

         -        tariffs and other barriers,
         -        difficulties in staffing and managing foreign subsidiary and
                  branch operations,
         -        currency exchange risks and exchange controls,
         -        potentially adverse tax consequences, and
         -        the possibility of difficulty in accounts receivable
                  collection.

Because many of Cymer's principal customers, as well as many of the end-users of
Cymer's laser systems, are located in Asia, the recent economic problems and
currency fluctuations affecting that region could intensify Cymer's
international risk. Further, while Cymer has experienced no


                                       23
<PAGE>

difficulty to date in complying with United States export controls, these rules
could change in the future and make it more difficult or impossible for Cymer to
export its products to various countries. These factors could have a material
adverse effect on Cymer's business, financial condition and results of
operations.

         CURRENCY FLUCTUATIONS

         Sales by Cymer to its Japanese subsidiary are denominated in dollars,
while sales by the subsidiary to customers in Japan are denominated in yen. This
means that Cymer's results of operations show some fluctuation based on the
value of the Japanese yen against the U.S. dollar. Cymer's Japanese subsidiary
manages its exposure to such fluctuations by entering into foreign currency
exchange contracts to hedge its purchase commitments. Management will continue
to monitor Cymer's exposure to currency fluctuations, and, when appropriate, use
financial hedging techniques to minimize the effect of these fluctuations.
However, exchange rate fluctuations might have a material adverse effect on
Cymer's results of operations or financial condition. In the future, Cymer might
need to sell its products in other currencies, which would make the management
of currency fluctuations more difficult and expose Cymer to greater risks in
this regard.

         FOREIGN REGULATIONS

         Numerous foreign government standards and regulations apply to Cymer's
products. These standards and regulations are continually being amended.
Although Cymer endeavors to meet foreign technical and regulatory standards,
Cymer's products might not continue to comply with foreign government standards
and regulations, or changes thereto. It might not be cost effective for Cymer to
redesign its products to comply with such standards and regulations. The
inability of Cymer to design or redesign products to comply with foreign
standards could have a material adverse effect on Cymer's business, financial
condition and results of operations.

ENVIRONMENTAL AND OTHER GOVERNMENT REGULATIONS

         Federal, state and local regulations impose various controls on the
storage, handling, discharge and disposal of substances used in Cymer's
manufacturing process and on the facility leased by Cymer. Cymer believes that
its activities conform to present governmental regulations applicable to its
operations and its current facilities. These regulations include those related
to environmental, land use, public utility utilization and fire code matters.
Such governmental regulations might in the future impose the need for additional
capital equipment or other process requirements upon Cymer. They might also
restrict Cymer's ability to expand its operations. The adoption of such
measures, or the failure by Cymer to comply with applicable environmental and
land use regulations or to restrict the discharge of hazardous substances, could
subject Cymer to future liability or could cause its manufacturing operations to
be curtailed or suspended.

RISKS OF PRODUCT LIABILITY CLAIMS

         Cymer faces a significant risk of exposure to product liability claims
in the event that the use of its products results in personal injury or death.
Cymer might experience material product liability losses in the future. Cymer
maintains insurance against product liability claims. However, such coverage
might not continue to be available on terms acceptable to Cymer. Such coverage
also might not be adequate for liabilities actually incurred. Further, in the
event that any of Cymer's products prove to be defective, Cymer may need to
recall or redesign such products. A successful claim brought against Cymer in
excess of available insurance coverage, or any claim or product recall that
results in significant adverse publicity against Cymer, could have a material
adverse effect on Cymer's business, financial condition and results of
operations.


                                       24
<PAGE>

POSSIBLE PRICE VOLATILITY OF COMMON STOCK

         The following factors may significantly affect the market price of
Cymer's Common Stock:

        -     actual or anticipated fluctuations in Cymer's operating results,
        -     announcements of technological innovations,
        -     new products or new contracts by Cymer or its competitors,
        -     developments with respect to patents or proprietary rights,
        -     conditions and trends in the laser device and other technology
              industries,
        -     changes in financial estimates by securities analysts,
        -     general market conditions, and
        -     other factors.

In addition, the stock market has experienced extreme price and volume
fluctuations that have particularly affected the market price for many high
technology companies. Such fluctuations have in some cases been unrelated to the
operating performance of these companies. Severe price fluctuations in a
company's stock have frequently been followed by securities litigation. Cymer is
currently in the process of defending such an action (see - "Legal Matters").
Such litigation can result in substantial costs and a diversion of management's
attention and resources.

LEGAL MATTERS

         Cymer has been named as a defendant in several putative shareholder
  class action lawsuits which were filed in September and October, 1998 in the
  U.S. District Court for the Southern District of California. Certain executive
  officers and directors of Cymer are also named as defendants. The plaintiffs
  purport to represent a class of all persons who purchased Cymer's Common Stock
  between April 24, 1997 and September 26, 1997 (the "Class Period"). The
  complaints allege claims under the federal securities laws. The plaintiffs
  allege that Cymer and the other defendants made various material
  misrepresentations and omissions during the Class Period. The complaints do
  not specify the amount of damages sought. The complaints have been
  consolidated into a single action and a class representative has been
  appointed by the court. A consolidated amended complaint was filed in early
  August, 1999. On November 5, 1999, Cymer and the other defendants filed a
  motion to dismiss the consolidated amended claim for failure to state a cause
  of action. On April 1, 2000, the court granted defendant's motion to dismiss
  with leave to amend the complaint by the plaintiffs. The plaintiffs filed
  their second amended complaint on June 5, 2000. Cymer moved to dismiss the
  amended complaint on August 4, 2000. Cymer believes it has meritorious
  defenses to the claims asserted and intends to defend the action vigorously.
  Accordingly, no provision for any liability or loss that may result from
  adjudication or settlement thereof has been made in the accompanying
  consolidated financial statements.

ANTI-TAKEOVER EFFECT OF NEVADA LAW AND CHARTER AND BYLAW PROVISIONS;
AVAILABILITY OF PREFERRED STOCK FOR ISSUANCE

         Nevada law as well as Cymer's charter and other documents contain
provisions that could discourage a proxy contest or make more difficult the
acquisition of a substantial block of Cymer's Common Stock, including Cymer's
Articles of Incorporation and Bylaws and Cymer's Preferred Shares Rights
Agreement ("poison pill") dated February 13, 1998. In addition, the Board of
Directors is authorized to issue, without shareholder approval, up to 5,000,000
shares of Preferred Stock. Such shares of Preferred Stock may have voting,
conversion and other rights and preferences that may be superior to those of the
Common Stock and that could adversely affect the voting power or other rights of
the holders of Common Stock. The Board of Directors could use the issuance of
Preferred Stock or of rights to purchase Preferred Stock to discourage an
unsolicited acquisition proposal.


                                       25
<PAGE>

         ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

FOREIGN CURRENCY RISK

         Cymer conducts business in several international currencies through its
worldwide operations. Due to the large volume of business Cymer manages in
Japan, the Japanese operation poses the greatest foreign currency risk. Cymer
uses financial instruments, principally forward exchange contracts, in Japan to
manage its foreign currency exposures. Cymer does not enter into forward
exchange contracts for trading purposes.

         Cymer enters into foreign currency exchange contracts in order to
reduce the impact of currency fluctuations related to purchases of Cymer's
inventories by Cymer Japan for resale under firm third-party sales commitments.
Net gains or losses are recorded on the date the inventories are received by
Cymer Japan (the transaction date) and are included in cost of product sales in
the consolidated statements of operations as the related sale is consummated.
Amounts due from/to the bank on contracts not settled as of the transaction date
are recorded as foreign exchange contracts receivable/payable in the
consolidated balance sheets.

         At June 30, 2000, Cymer had outstanding forward foreign exchange
contracts to buy US$71.3 million for 7.4 billion yen under foreign currency
exchange facilities with contract rates ranging from 101.73 yen to 109.31 yen
per US$ and various expiration dates through May 2001.

INVESTMENT AND DEBT RISK

         Cymer maintains an investment portfolio consisting primarily of
government and corporate fixed income securities, certificates of deposit and
commercial paper. While it is Cymer's general intent to hold such securities
until maturity, management will occasionally sell particular securities for cash
flow purposes.* Therefore, Cymer's investments are classified as
available-for-sale and are carried on the balance sheet at fair value. Due to
the conservative nature of the investment portfolio, a sudden change in interest
rates would not have a material effect on the value of the portfolio.

         In August 1997, Cymer issued $172.5 million aggregate principal amount
of Step-Up Convertible Subordinated (Notes) due August 6, 2004, with interest
payable semi-annually February 6 and August 6, commencing February 6, 1998.
Interest on the notes is stated at 3 1/2% per annum from August 6, 1997 through
August 5, 2000 and at 7 1/4% per annum from August 6, 2000 to maturity or
earlier redemption, representing a yield to maturity accrued at approximately
5.47%. The Notes are convertible at the option of the holder into shares of
Common Stock of Cymer at any time on or after November 5, 1997 and prior to
redemption or maturity, at a conversion rate of 21.2766 shares per $1,000
principal amount of Notes, subject to adjustment under certain conditions. Cymer
cannot redeem the Notes prior to August 9, 2000. Thereafter, Cymer can redeem
the Notes from time to time, in whole or in part, at specified redemption
prices. The Notes are unsecured and subordinated to all existing and future
senior indebtedness of Cymer. The indenture governing the Notes does not
restrict the incurrence of senior indebtedness or other indebtedness by Cymer.
These Notes are recorded at face value on the consolidated balance sheets. The
fair value of such debt, based on quoted market prices at June 30, 2000 was
$206.5 million. As of December 31, 1999, $172.5 million in Convertible
Subordinated Notes was outstanding, as compared to $172.3 million outstanding as
of June 30, 2000.


                                       26
<PAGE>

                           PART II. OTHER INFORMATION


ITEM 1.           Legal Proceedings

                           Cymer has been named as a defendant in several
                  putative shareholder class action lawsuits which were filed in
                  September and October, 1998 in the U.S. District Court for the
                  Southern District of California. Certain executive officers
                  and directors of Cymer are also named as defendants. The
                  plaintiffs purport to represent a class of all persons who
                  purchased Cymer's Common Stock between April 24, 1997 and
                  September 26, 1997 (the "Class Period"). The complaints allege
                  claims under the federal securities laws. The plaintiffs
                  allege that Cymer and the other defendants made various
                  material misrepresentations and omissions during the Class
                  Period. The complaints do not specify the amount of damages
                  sought. The complaints have been consolidated into a single
                  action and a class representative has been appointed by the
                  court. A consolidated amended complaint was filed in early
                  August, 1999. On November 5, 1999, Cymer and the other
                  defendants filed a motion to dismiss the consolidated amended
                  claim for failure to state a cause of action. On April 1,
                  2000, the court granted defendant's motion to dismiss with
                  leave to amend the complaints by the plaintiffs. The
                  plaintiffs filed their second amended complaint on June 5,
                  2000. Cymer moved to dismiss the amended complaint on August
                  4, 2000. Cymer believes it has meritorious defenses to the
                  claims asserted and intends to defend the action vigorously.
                  Accordingly, no provision for any liability or loss that may
                  result from adjudication or settlement thereof has been made
                  in the accompanying consolidated financial statements.

ITEM 2.           Changes in Securities and Use of Proceeds

                  None.

ITEM 3.           Defaults upon Senior Securities

                  None.

ITEM 4.           Submission of Matters to a Vote of Security Holders

                  Cymer held its Annual Meeting of Stockholders on May 18, 2000.
                  Out of 28,944,953 shares of common stock entitled to vote at
                  such meeting, there were present in person or by proxy
                  23,299,476 shares. At the Annual Meeting, the stockholders of
                  Cymer approved the following matters:

                  (a) The election of Robert P. Akins, Richard P. Abraham,
                      Kenneth M. Deemer, Peter J. Simone and Jon D. Tompkins as
                      directors of Cymer for the ensuing year and until their
                      successors are elected. The vote for the nominated
                      directors was as follows:

                      Robert P. Akins, 23,272,407 votes cast for, 27,069 votes
                      withheld and 2,368 exception votes; Richard P. Abraham,
                      23,193,106 votes cast for, 106,370 votes withheld and
                      81,669 exception votes; Kenneth M. Deemer, 23,196,722
                      votes cast for, 102,754 votes withheld and 78,053
                      exception votes; Peter J. Simone, 23,180,753 votes cast
                      for, 118,723 votes withheld and 94,022 exception votes;
                      Jon D. Tompkins, 23,237,302 votes cast for, 62,174 votes
                      withheld and 37,473 exception votes;


                                       27
<PAGE>

                  (b) Approval of a 1,400,000 share increase in shares issuable
                      under the 1996 Stock Option Plan. 14,514,882 votes were
                      cast for approval; 8,723,175 votes were cast against, and
                      61,419 votes abstained.

                  (c) Ratification of the appointment of KPMG LLP as the
                      independent auditors of Cymer for the year ending December
                      31, 2000. 23,228,377 votes were cast for approval; 48,479
                      votes were cast against and 22,620 votes abstained.

ITEM 5.           Other Information

                  None.

ITEM 6.  Exhibits and Reports on Form 8-K

                  (a) Exhibits

                  10.1   Employment Agreement, dated May 8, 2000, by and
                         between Brian Klene and Cymer.

                  27.1   Financial Data Schedule (submitted for SEC use only)

                  (b) Reports on Forms 8-K

                  Current report on Form 8-K filed April 13, 2000 reporting that
                  Cymer engaged KPMG LLP on April 12, 2000 as its independent
                  accountants to audit its consolidated financial statements for
                  the year ending December 31, 2000.


                                       28
<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                                                 CYMER, INC.
                                                 (Registrant)


Date:  August 10, 2000                  By:    /s/ WILLIAM A. ANGUS, III
                                               -------------------------

                                                 William A. Angus, III
                                                 Sr. Vice President and
                                                 Chief Financial Officer
                                                 (Duly Authorized Officer and
                                                 Principal Financial Officer)


                                       29


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission